Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US House Energy & Commerce Committee Lays Out Medtech Agenda, Membership, For 2021 Congress

Committee to address coronavirus testing, telehealth access, FDA regulations, consumer fraud and other related device issues this session

Executive Summary

The House E&C committee and its subpanels will address coronavirus testing, FDA device regulation and cybersecurity during the upcoming 117th Congress.

You may also be interested in...

Pandemic Emergency Manufacturing Act Introduced In US Congress

The bill authorizes a federal emergency office of manufacturing to make needed COVID-19 supplies.

Exclusive: Top Medical Device Lobbyist On User-Fee Talks, Biden And New Congress, Implementing MCIT Rule

The MDMA’s Mark Leahey talked with Medtech Insight about how the medical device industry responded to the COVID-19 pandemic, plans for working with a new administration and Congress, and hopes for the MDUFA negotiations.

Senate Passes Fourth COVID-19 Spending Package, Includes $25Bn For Additional Testing, Contact Tracing

A Paycheck Protection Program and Health Care Enhancement Act bill that would dole out $25bn for additional testing by federal agencies and $75bn to Medicare suppliers providing testing equipment passed the US Senate on 21 April and is headed to the House for a vote.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts